Securities code: Shanghai Pharmaceuticals Holding Co.Ltd(601607) securities abbreviation: Shanghai Pharmaceuticals Holding Co.Ltd(601607) No.: pro 2022031
Shanghai Pharmaceuticals Holding Co.Ltd(601607)
Announcement on the proposed issuance of debt financing products
The board of directors and all directors of the company guarantee that there are no false records and misleading statements in the contents of this announcement
Or major omission, and bear individual and joint liabilities for the authenticity, accuracy and integrity of its contents
In order to further broaden the financing channels of Shanghai Pharmaceuticals Holding Co.Ltd(601607) (hereinafter referred to as “the company” or “the company”), optimize the debt structure of the company, reasonably control the financial cost, and enable the company to flexibly select financing instruments to meet the capital needs in time, according to relevant regulations, the company plans to issue various short-term debt financing products and medium and long-term debt financing products with a balance of no more than 15 billion yuan, The categories of financing products include but are not limited to short-term financing bonds, ultra short-term financing bonds, short-term corporate bonds, medium-term notes, medium and long-term corporate bonds, perpetual bonds, quasi perpetual bonds, asset-backed notes, green debt financing instruments and other short-term, medium and long-term debt financing products. 1、 Distribution scheme
1. Issuance scale
The company plans to apply for issuing various short-term debt financing products and medium and long-term debt financing products with a balance of no more than 15 billion yuan. The categories of financing products include but are not limited to short-term financing bonds, ultra short-term financing bonds, short-term corporate bonds, medium-term notes, medium and long-term corporate bonds, perpetual bonds, quasi perpetual bonds, asset-backed notes, green debt financing instruments and other short-term and medium and long-term debt financing products.
2. Release time
According to the actual capital demand, the company will issue one-time or installment within the validity period of regulatory approval or registration of relevant products.
3. Purpose of raised funds
The funds raised by the company’s issuance of debt financing products will be used to supplement the working capital of the company and its subsidiaries and repay debts.
4. Term of issue
The financing period of various short-term debt financing products to be registered and issued by the company shall not exceed 1 year (including 1 year). The financing period of various medium and long-term debt financing products to be registered and issued will be determined according to the capital needs of the company and market conditions.
5. Validity of resolution
The validity period of this resolution is 12 months from the date of deliberation and approval by the general meeting of shareholders of the company. During the aforesaid validity period, the validity period of this resolution shall be automatically extended to the date when the amount of debt financing products for which the company has submitted the issuance application to the relevant regulatory authorities is fully issued, or the date when the relevant regulatory authorities approve / register the amount of debt financing products for which the issuance application has been submitted, whichever is later. During the above-mentioned validity period, the amount of debt financing products for which the company has not submitted an issuance application to the relevant regulatory authorities will automatically become invalid upon the expiration of the above-mentioned validity period. During the aforesaid validity period, the company may hold a separate general meeting of shareholders on the issuance of debt financing products to decide whether to terminate or extend the validity of this resolution. 2、 Authorization matters related to issuance
In order to better grasp the issuance opportunity of debt financing products and improve financing efficiency, the general meeting of shareholders is hereby requested to authorize the board of directors of the company and the Executive Committee of the board of directors to fully handle specific matters related to the issuance of debt financing products, including but not limited to:
1. According to national laws and regulations, relevant regulations and policies of regulatory authorities and resolutions of the general meeting of shareholders and the board of directors of the company, formulate and implement specific plans for the issuance and decide on specific matters for the issuance and listing of debt financing products, including but not limited to negotiating with the lead underwriter to determine or adjust the types and amounts of the issuance according to the needs of the company and market conditions Whether to issue by stages and determine the arrangement of issuance amount, issuance timing, term and method of principal and interest repayment, issuance method, whether to set resale terms or redemption terms, determine and hire intermediary institutions, underwriting method, rating arrangement, pricing method, coupon rate or its determination method, specific details of the use of raised funds, debt repayment guarantee measures, guarantee and other credit enhancement matters within the validity period of registration notice or regulatory approval Listing and issuance of debt financing products.
2. Make necessary modifications and adjustments to the issuance plan and issuance related documents according to the opinions of regulatory authorities and / or changes in market conditions.
3. Represent the company in negotiations related to the issuance and listing of debt financing products, sign contracts, agreements and other legal documents related to the issuance and listing of debt financing products, and make appropriate information disclosure.
4. Take all necessary actions to decide / handle other specific matters related to the issuance and listing of debt financing products.
5. The above authorization matters shall be valid within 12 months from the date of deliberation and approval by the general meeting of shareholders. During the aforesaid validity period, the validity period of this resolution shall be automatically extended to the date when the amount of debt financing products for which the company has submitted the issuance application to the relevant regulatory authorities is fully issued, or the date when the relevant regulatory authorities approve / register the amount of debt financing products for which the issuance application has been submitted, whichever is later. During the above-mentioned validity period, the amount of debt financing products for which the company has not submitted an issuance application to the relevant regulatory authorities will automatically become invalid upon the expiration of the above-mentioned validity period. During the aforesaid validity period, the company may hold a separate general meeting of shareholders on the issuance of debt financing products to decide whether to terminate or extend the validity of this resolution. 3、 Approval procedures related to issuance
The issuance plan and authorization of the company’s debt financing products need to be submitted to the general meeting of shareholders for deliberation and approval, and can be implemented only after the issuance is approved by relevant competent authorities. The company will timely disclose the relevant issuance in accordance with the provisions of relevant laws and regulations.
It is hereby announced.
Shanghai Pharmaceuticals Holding Co.Ltd(601607) board of directors
March 30, 2022
